&lt;p&gt;Galectin-3 as a prognostic biomarker for diabetic nephropathy&lt;/p&gt;

Hodeib, Hossam; Hagras, Maha M; Watany, Mona Mohamed; Selim, Amal; Tawfik, Mohamed A; Elsebaey, Mohamed A; Elshweikh, Samah A

doi:10.2147/dmso.s194410

Cited by 16 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, the association of Gal3 and diabetic microvascular complications has been studied. Gal3 has been considered as a prognostic biomarker and independently associated with the progression of diabetic nephropathy 20,21 . Gal3 was also identified as an independent risk factor of diabetic retinopathy and optic nerve disorders 9 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin‐3 level

et al. 2020

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction Galectin‐3 (Gal3) contributes to insulin resistance, inflammation and obesity, the three risk factors for mild cognitive impairment (MCI) in type 2 diabetes mellitus patients. Materials and methods A total of 134 hospitalized type 2 diabetes mellitus patients were assessed by the Montreal Cognitive Assessment method, and divided into 65 MCI and 69 controls. Levels of variables, Gal3 and Aβ42, were investigated in relation with cognitive function in both type 2 diabetes mellitus patients with MCI and high‐fat diet/streptozotocin induced type 2 diabetes mellitus rats. Results Significantly higher levels of serum Gal3 and lower levels of plasma Aβ42 (all P < 0.05) were found in the MCI type 2 diabetes mellitus group as compared with the non‐MCI type 2 diabetes mellitus control. Partial correlation analysis showed that Gal3 is negatively correlated with both MMSE score (r = −0.51, P < 0.01) and Montreal Cognitive Assessment score (r = −0.47, P < 0.001) after adjustment for glycated hemoglobin, homoeostasis model assessment of insulin resistance and Aβ42 in all type 2 diabetes mellitus patients, with a stronger effect seen in the MCI type 2 diabetes mellitus group after further analysis with MCI strata. A simple logistic regression model showed that Gal3 and Aβ42 are significantly associated with MCI type 2 diabetes mellitus patients after adjustment with the covariates sex, age, body mass index, glycated hemoglobin, homoeostasis model assessment of insulin resistance and antidiabetic drugs. Serum and brain Gal3 levels were significantly increased in high‐fat diet/streptozotocin diabetic rats, which correlate to the impairment of learning and memory ability. Gal3 inhibitor modified citrus pectin decreased serum and brain Gal3 levels in diabetic rats, accompanied by the amelioration of learning and memory impairment. Conclusions Gal3 might be associated with cognitive impairment in type 2 diabetes mellitus, and serum Gal3 level might be a new risk factor of MCI in type 2 diabetes mellitus patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin‐3 level

et al. 2020

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…On the other hand, serum levels of Gal-3 levels were associated with an increased risk of all-cause mortality and cardiovascular events in patients with CKD [ 90 ]. In patients with T2D, the mean levels of Gal-3 were significantly higher in patients with macroalbuminuria (urinary albumin/creatinine ratio (ACR) = >300 mg/g) than in those with microalbuminuria (30–300 mg/g) and normoalbuminuria (ACR = <30 mg/g) [ 91 ]. Gal-3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity [ 92 ].…”

Section: Common Drug Pipelines For Nafld/nash and Diabetic Nephropmentioning

confidence: 99%

Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?

Sumida

Yoneda

Toyoda

et al. 2020

IJMS

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called “diabetic hepatopathy or diabetic liver disease”. NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy.

show abstract

“…It is present in both intracellular and extracellular spaces. Extracellular Gal-3 reacts with galactoside remains of extracellular matrix and cell surface glycoproteins through its C-terminal carbohydrate-recognition part, while intracellular Gal-3 reacts peptide-peptide interactions through its N terminal part (6,7). Such structure and position properties have identified that Gal-3 takes part in several biological processes, including oxidative stress, apoptosis, vascular lesion, inflammation, and the progress of insulin resistance that may affect cardiovascular function and progression of chronic hyperglycemia (8).…”

Section: Introductionmentioning

confidence: 99%

Associations of galectin-3 expression and LGALS-3 (rs4652) gene variant with coronary artery disease risk in diabetics

et al. 2021

View full text Add to dashboard Cite

Background Galectin‑3 protein that is encoded by lectin galactoside-binding soluble-3 (LGALS-3) gene serves as an important genetic factor in type 2 diabetes mellitus (T2DM) and its cardiovascular obstacles in various populations. We aimed to elicit the pro-inflammatory effect of galectin-3 as determined by interleukin-6 (IL-6) serum levels and to explore the relationship between galectin-3 (LGALS-3 rs4652) gene variation and its expression levels with coronary artery disease (CAD) risk among T2DM Egyptian patients. Methods: 112 lean subjects were compared to 100 T2DM without CAD and 84 T2DM with CAD. A tetra-primer amplification refractory mutation system polymerase chain reaction was used to test LGALS-3 (rs4652) and galectin-3 expression was tested with a quantitative real-time polymerase chain reaction. Serum IL-6 was measured using an enzyme-linked immunosorbent assay. Results: We found that the prevalence of LGALS-3 (rs4652) AC genotype and galectin-3 gene expression levels in T2DM with CAD were significantly higher than the additional 2 groups and were correlated positively to IL-6 circulating levels also, the C allele carriers (AC+CC) had significantly higher relative Galectin-3 expression levels compared to the A allele carriers (AA). Conclusion: We concluded that galectin-3 expression levels and LGALS-3 (rs4652) AC genotype were coronary artery disease risk factors in type two diabetics among an Egyptian sample.

show abstract

<p>Galectin-3 as a prognostic biomarker for diabetic nephropathy</p>

Cited by 16 publications

References 26 publications

Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin‐3 level

Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin‐3 level

Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?

Associations of galectin-3 expression and LGALS-3 (rs4652) gene variant with coronary artery disease risk in diabetics

Contact Info

Product

Resources

About